Fexuprazaniii is superior to Esomerazole

South Korea's Daewoong Pharmaceutical Company recently released the first phase III clinical data of the new gastroesophedic reflow drug fexuprazan at Digestive Disease Week 2020 (DDW), confirming that fexuprazan has significant effects and good safety in inhibiting gastric acid secretion. It is worth mentioning that the fexuprazan summary was named the TOP 10% summary of all posters selected by the American Gastroenterology Association (AGA) and was selected as an outstanding poster for the DDW period.
fexuprazan is a new type of potassium ion competitive acid blocker (P-CAB), a next-generation proton pump inhibitor (PPI) that irreversibly blocks proton pumps that secrete stomach acid. At present, PPI has been widely used in the treatment of gastroesoesotic refract disease (GERD).Daewoong has conducted a Phase III clinical trial in South Korea for the treatment of patients with rotting esophagitis, and clinical trials for other acid-related diseases are under way.The Phase III trial, conducted at 25 hospitals in South Korea, assessed the efficacy and safety of fexuprazan in treating patients with rotting esotheritis. The results showed that fexuprazan showed a 99% mucosal healing rate in the 8th week of treatment and good patient tolerance. Fexuprazan also showed improved symptom relief. In particular, in patients with moderate to severe symptoms, fexuprazan showed significantly faster and better heartburn relief than Esomeprazole (Nexium, Essum), and this heartburn relief was maintained at night. In addition, fexuprazan treatment can also improve atypical symptoms such as cough.Dr Oh Young Lee, Co-Research Fellow in Gastroenterology, Hanyang University Hospital, South Korea, said: "Through these very promising Phase III trial results in patients with rotting esoitis, fexuprazan has proven to be the best choice for the treatment of gastroesoesotic reflow disease (GERD), which meets the unseemly medical needs of current treatments by providing rapid and effective heartburn relief and endoscopic healing. Sengho Jeon
chief executive of daewoong, said: "We are committed to developing a new and improved treatment and we are delighted to see fexuprazan as a valuable complement to the current treatment of acid-related diseases. We hope to accelerate the development of fexuprazan through partnerships and will soon have a unique opportunity to commercialize fexuprazan in global markets such as the United States and China. In
, Daewoong signed an agreement with Moksha8, Latin America's leading pharmaceutical company. Fexuprazan is expected to be the next best-selling drug in the $37 billion anti-acid secretion market as Daewoong begins its successful entry into the global market.
(Bio Valley
)